Physician profile
Heba Ashraf
NPI 1720492267
$8,550.94
in general payments reported to CMS, 2019-2025
38 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $358 · 2021: $705 · 2022: $912 · 2023: $1,415 · 2024: $1,359 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,643 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,642.86 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.57 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Aimmune Therapeutics, INC. | $690.44 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $637.58 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $454.82 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $438.82 | 2019-2022 | |
| Madrigal Pharmaceuticals | $405.10 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $386.60 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $362.19 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $354.26 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.23 | 2019-2024 | Xifaxan |
| Medtronic, INC. | $303.55 | 2023-2025 | Nexpowder, Endoflip, Bravo |
| Celgene Corporation | $217.15 | 2023 | Zeposia |
| Gilead Sciences, INC. | $216.42 | 2020-2022 | |
| Cook Medical LLC | $215.50 | 2020-2025 | Hemospray |
| Phathom Pharmaceuticals, INC. | $171.84 | 2024 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $164.43 | 2025 | Omvoh |
| Novo Nordisk INC | $153.75 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $143.56 | 2022-2024 | Andexxa |
| Nestle Healthcare Nutrition INC. | $133.78 | 2023 | |
| Mallinckrodt Hospital Products INC. | $121.82 | 2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.35 | 2019 | |
| Greenwich Biosciences, INC. | $116.42 | 2019 | |
| Intercept Pharmaceuticals, INC. | $116.19 | 2022 | |
| Glaxosmithkline, LLC. | $108.76 | 2019 | |
| Ambu INC. | $97.34 | 2021 | |
| Celltrion USA INC. | $59.12 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $57.38 | 2025 | Dupixent |
| Daiichi Sankyo INC. | $30.84 | 2022 | |
| Braintree Laboratories, INC. | $29.09 | 2025 | Suflave, Sutab |
| Phadia US INC. | $19.47 | 2023 | Immunocap |
| Vivus LLC | $19.38 | 2023 | Qsymia |
| Conmed Corporation | $19.36 | 2024 | Conmed Eus |
| Intuitive Surgical, INC. | $17.60 | 2024 | |
| Ardelyx, INC. | $15.69 | 2023 | Ibsrela |
| Evoke Pharma, INC. | $15.62 | 2023 | Gimoti |
| Alexion Pharmaceuticals, INC. | $14.07 | 2019 | |
| Qol Medical, LLC | $13.62 | 2024 | Sucraid |
| Pfizer INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heba Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.